All In Biotech

Drug Trial Radar · NCT06493552

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Mar 15, 2025

Primary completion

Sep 2029

Study completion Aug 2034

Sponsor

Lead sponsor
Vasgene Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jul 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of disease or unacceptable toxicities arise.

Conditions

  • Muscle-Invasive Bladder Carcinoma
  • Metastatic Urothelial Carcinoma

Interventions

  • SEphB4-HSADrug

    A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.

  • PembrolizumabDrug

    Antibody to human PD-1.

  • GemcitabineDrug

    A chemotherapy drug used to treat various types of cancer.

  • CisplatinDrug

    A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.

  • Enfortumab vedotinDrug

    Nectin-4-directed antibody and microtubule inhibitor conjugate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improved pathological response (pCR) in sEphB4-HSA+Pembro vs. Standard of Care for MIBCTime frame: Through study completion, an average of 6 months
  2. Improved Overall Survival (OS) in sEphB4-HSA+Pembro vs. Standard of Care for MIBCTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
  3. Improved Radiographic Objective Response Rate (ORR) in sEphB4+Pembro vs. Control in mUCTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
  4. Non-inferior Overall Survival (OS) of sEphB4+Pembro vs. Control in mUCTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sarcoma Oncology Center

    Santa Monica, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.